Therefore, our findings not only indicate the possibility of c‐MET activation as the molecular mechanism underlying cigarette smoke‐related EGFR TKI resistance, but also suggest that c‐MET inhibitors may benefit NSCLC patients who smoke, who harbor wtEGFR‐expression. This evidence concerns the gene EGFR and non-small cell lung carcinoma.